Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.9K
Measurement: Standard Units03:38

Measurement: Standard Units

81.3K
Every measurement provides three kinds of information: the size or magnitude of the measurement (a number), a standard of comparison for the measurement (a unit), and an indication of the uncertainty of the measurement. While the number and unit are explicitly represented when a quantity is written, the uncertainty is an aspect of the errors in the measurement results.
81.3K
Lung Capacity01:47

Lung Capacity

56.4K
The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.4K
Sustainable Development01:43

Sustainable Development

15.2K
As the human population continues to grow and use resources, we must be mindful of our planet’s natural limits. Sustainable development provides a pathway to maintain and improve human life now while also ensuring that future generations will have the resources that they need. The long-term success of sustainability efforts rests on understanding the interplay between human actions and ecological systems.
15.2K
Electrical Current01:10

Electrical Current

7.2K
Electrical current is defined as the rate at which charge flows. When there is a large current present, such as that used to run a refrigerator, a large amount of charge moves through the wire in a small amount of time. If the current is small, such as that used to operate a handheld calculator, a small amount of charge moves through the circuit over a long period of time. The SI unit for current is the ampere (A), named for the French physicist André-Marie Ampère (1775–1836).
7.2K
Standard Enthalpy of Formation02:37

Standard Enthalpy of Formation

49.3K
Enthalpy changes are typically tabulated for reactions in which both the reactants and products are at the same conditions. A standard state is a commonly accepted set of conditions used as a reference point for the determination of properties under other different conditions. For chemists, the IUPAC standard state refers to materials under a pressure of 1 bar and solutions at 1 M and does not specify a temperature. Many thermochemical tables list values with a standard state of 1 atm. Because...
49.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brief report: Artificial intelligence meets small cell lung cancer-integrating clinicopathological and wholeslide image data for prognostic prediction in SCLC.

Frontiers in artificial intelligence·2026
Same author

Emerging Targeted Therapies for HER2-Mutant NSCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

First-Line Zongertinib in Advanced <i>HER2</i>-Mutant Non-Small-Cell Lung Cancer.

The New England journal of medicine·2026
Same author

SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in <i>KRAS</i> G12C NSCLC.

Future oncology (London, England)·2026
Same author

Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.

The New England journal of medicine·2026
Same author

Combination of Lurbinectedin Plus Irinotecan: Preclinical and Early Clinical Results in Patients With Relapsed SCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Related Experiment Video

Updated: Feb 8, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

419

Targeting EGFR in Lung Cancer: Current Standards and Developments.

Asunción Díaz-Serrano1,2, Pablo Gella2, Elisabeth Jiménez1,2

  • 1Medical Oncology Department, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain.

Drugs
|June 20, 2018
PubMed
Summary

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) treat EGFR-mutant non-small cell lung cancer (NSCLC). Osimertinib shows promise, but resistance mechanisms necessitate further research into novel therapies.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.6K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.5K

Related Experiment Videos

Last Updated: Feb 8, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

419
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.6K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.5K

Area of Science:

  • Oncology
  • Medical Genetics
  • Pharmacology

Background:

  • Lung cancer is a leading cause of cancer death globally.
  • Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) represents a significant subset of lung malignancies.
  • First- and second-generation EGFR tyrosine kinase inhibitors (TKIs) have improved treatment outcomes for EGFR-mutant NSCLC.

Purpose of the Study:

  • To review the efficacy of EGFR TKIs in treating NSCLC.
  • To discuss resistance mechanisms to EGFR TKIs, including the T790M mutation.
  • To explore emerging therapeutic strategies for overcoming TKI resistance in EGFR-mutant NSCLC.

Main Methods:

  • Literature review of clinical trials and research studies on EGFR TKIs.
  • Analysis of resistance mechanisms to first-, second-, and third-generation EGFR TKIs.
  • Overview of ongoing investigations into fourth-generation TKIs, combination therapies, and immunotherapy.

Main Results:

  • First- and second-generation EGFR TKIs offer benefits but are associated with resistance, notably the T790M mutation.
  • Osimertinib demonstrates improved progression-free survival and central nervous system metastasis control.
  • The FLAURA trial indicated a PFS advantage for osimertinib over first-generation inhibitors in first-line therapy.

Conclusions:

  • Osimertinib is a valuable therapeutic option for EGFR-mutant NSCLC, particularly in the second-line setting.
  • Understanding diverse resistance mechanisms is crucial for developing next-generation treatments.
  • Ongoing research into novel TKIs, combination therapies, and immunotherapies holds promise for improving outcomes in EGFR-mutant NSCLC.